'Real-life' effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study
| Autor: | MinKyoung Song, Ivo Abraham, Guy Brusselle, Alain Michils, Sandra Gurdain, Christine Hermans, Stefaan Vancayzeele, Lieven Dupont, Christopher S. Lee, Renaud Louis, Charles Pilette, P. Lecomte, A. Delobbe, Karen MacDonald, B. Van de Maele |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Allergy Severe asthma Exacerbation business.industry Allergic asthma Omalizumab medicine.disease Asthma Quality of life Internal medicine Severity of illness Physical therapy Medicine Young adult business Prospective cohort study medicine.drug |
| Zdroj: | Respiratory Medicine. (11):1633-1642 |
| ISSN: | 0954-6111 |
| DOI: | 10.1016/j.rmed.2009.06.014 |
| Popis: | SummaryObjectiveTo evaluate the 16- and 52-week effectiveness of add-on omalizumab treatment under real-life heterogeneity in patients, settings, and physicians in an open-label, multicenter, pharmaco-epidemiologic study of patients with severe persistent allergic asthma in Belgium.MethodsEffectiveness outcomes included improvement in 2005 global initiative for asthma (GINA) classification, physician-rated global evaluation of treatment effectiveness (GETE), quality of life (Juniper asthma-related quality of life (AQLQ) and European quality of life questionnaire 5 dimensions (EQ-5D)), and severe asthma exacerbations. Patients studied included both intent-to-treat and per-protocol populations.ResultsThe sample (n=158) had a mean age of 48.17±17.18 years, and a slight majority were female (53.8%). Despite being treated with high-dose inhaled corticosteroids and long-acting β2-agonists, all patients experienced frequent symptoms and had exacerbations in the past year. At 16 weeks, >82% had good/excellent GETE (P values 82% had an improvement in total AQLQ scores of ≥0.5 points (P91% were severe exacerbation-free (P72% had a good/excellent GETE rating (P84% had improvements in total AQLQ score of ≥0.5 points (P56% had minimally important improvements in EQ-5D utility scores (P=0.012), and >65% were severe exacerbation-free (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|